Sodium-glucose cotransporter inhibitors: beyond glycaemic control
نویسندگان
چکیده
منابع مشابه
Sodium-Glucose Cotransporter 2 Inhibitors: Possible Anti-Atherosclerotic Effects Beyond Glucose Lowering
The new drug for type 2 diabetes, the sodium-glucose cotransporter 2 (SGLT-2) inhibitor, is reversible inhibitor of SGLT-2, leading to reduction of renal glucose reabsorption and decrease of plasma glucose, in an insulin-independent manner. In addition to glucose control, the management of coronary risk factors is very important for patients with diabetes. Here we reviewed published articles ab...
متن کاملSodium-Glucose Cotransporter 2 Inhibitors for Heart Failure
In this issue (P94), Kutoh reports type 2 diabetic patients who showed changes in cardiac function which is concomitant with changes in ketone bodies by using one of sodium glucose cotransporter 2 inhibitors (SGLT2i), tofogliflozin [1], proposing a possible mechanism for SGLT2i-mediated prevention of heart failure. EMPA-REG OUTCOME trial showed a striking relative risk reduction in hospitalizat...
متن کاملImpact of sodium–glucose cotransporter 2 inhibitors on blood pressure
SGLT2 inhibitors are glucose-lowering agents used to treat type 2 diabetes mellitus (T2DM). These agents target the kidney to promote urinary glucose excretion, resulting in improved blood glucose control. SGLT2-inhibitor therapy is also associated with weight loss and blood pressure (BP) lowering. Hypertension is a common comorbidity in patients with T2DM, and is associated with excess morbidi...
متن کاملCardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms.
The mechanism of action of empagliflozin in reducing the risk of adverse cardiovascular outcomes vs placebo in patients with type 2 diabetes mellitus and a high risk of cardiovascular disease in the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) trial is currently unknown. An antiatherosclerotic effect is consider...
متن کاملHemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitors
It is widely accepted that obesity and type 2 diabetes mellitus (T2DM) increase the risk of heart failure (HF) independently of underlying coronary artery disease. The changes in myocardial structure or function associated with diabetes have been termed diabetic cardiomyopathy. Corresponding to changes in the risk factors for HF, an epidemiologic transition is underway from HF with a reduced ej...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Kidney Journal
سال: 2019
ISSN: 2048-8513
DOI: 10.1093/ckj/sfz019